Bioinvent International Ab · OMXSTO:BINV
Bioinvent International Ab — Investor Presentation (October 2018)
31 slides from Bioinvent International Ab's investor presentation, Oct 17, 2018
Slide 1: Advancing Cancer Immunotherapies
Translating cancer antibody biology for life ADVANCING CANCER IMMUNOTHERAPIES Nasdaq Stockholm: BINV.ST ~ 350 million ordinary shares outstanding October 2018 Market Capitalization: ~ €90 million 1
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in BioInvent International AB (“BioInvent”). Neither shall the presentation or an
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS – Leading antibody immuno-oncology platform: • Advancing IO by overcoming tumor resistance • Validated by publications in top-tier journals and partnerships – Robust pipeline fueled by strong, fully integrated research engine: • 2 proprietary programs in the clinic - key readou
Slide 4: New drugs and mechanisms are needed to improve cancer immunotherapy & survival
NEW DRUGS AND MECHANISMS ARE NEEDED TO IMPROVE CANCER IMMUNOTHERAPY & SURVIVAL T H E CO N C E P T O N LY A S U B S E T O F A R A P I D LY WO R K S : PAT I E N TS R ES P O N D G ROW I N G M A R K E T: TO C U R R E N T D R U G S : New drugs direct the New mechanisms and Expected to reach sales immune
Slide 5: BioInvent targets key immune suppressive cells & mechanisms to boost anti-cancer immunity
BIOINVENT TARGETS KEY IMMUNE SUPPRESSIVE CELLS & MECHANISMS TO BOOST ANTI-CANCER IMMUNITY
Slide 6: F.I.R.S.T platform for discovery of novel oncology targets and mAb
F.I.R.S.T™- A PATIENT CENTRIC PLATFORM FOR DISCOVERY OF NOVEL ONCOLOGY TARGETS AND MAB
Slide 7: Pipeline – Multiple Value Drivers
PIPELINE – MULTIPLE VALUE DRIVERS indication target program discovery preclinical Phase I Phase II NHL BI-1206 / (MCL, MZL, iFL) rituximab solid cancer FcγRIIB αFcγRIIB solid cancer BI-1607 αCTLA-4-GM- solid cancer CSF-VV Tregs αTNFRS solid cancer (Emerging) solid cancer F.I.R.S.T™ αTreg solid cance
Slide 8: FcγRIIB – A single inhibitory antibody checkpoint to unlock anti-cancer immunity
FcγRIIB – A SINGLE INHIBITORY ANTIBODY CHECKPOINT TO UNLOCK ANTI-CANCER IMMUNITY 8 8
Slide 9: FcγRIIB – A single inhibitory antibody checkpoint to unlock anti-cancer immunity
FcγRIIB – A SINGLE INHIBITORY ANTIBODY CHECKPOINT TO UNLOCK ANTI-CANCER IMMUNITY Innate immunity Adaptive Adaptive immunity immunity 9 9
Slide 10: FcγR-interactions co-determine efficacy of checkpoint inhibitor antibodies
FcγR-INTERACTIONS CO-DETERMINE EFFICACY OF CHECKPOINT INHIBITOR ANTIBODIES Fc effector function contributes to the activity of Fcγ receptors modulate the anti-tumor activity of human anti-CTLA-4 antibodies antibodies targeting the PD-1/PD-L1 axis Vargas et al Cancer Cell 2018 Dahan et al Cancer Cell
Slide 11: BI-1206 in NHL: Turbocharging anti-CD20 - $500 million market opportunity
BI-1206 IN NHL: TURBOCHARGING ANTI-CD20- $500 MILLION MARKET OPPORTUNITY 11 11
Slide 12: BI-1206 in NHL: Turbocharging anti-CD20 - $500 million market opportunity
BI-1206 IN NHL: TURBOCHARGING ANTI-CD20- $500 MILLION MARKET OPPORTUNITY 12 12
Slide 13: BI-1206: Cutting both ways
BI-1206: CUTTING BOTH WAYS Human CD20 FcγRIIB Humanized model of double transgenic mice relapsed/refractory CLL % objective responders (blue) From Roghanian et al Cancer Cell 2015, 27, 473 13 13
Slide 14: BI-1206: Expanding therapeutic potential - Phase I/IIa study
BI-1206: EXPANDING THERAPEUTIC POTENTIAL - PHASE I/IIA STUDY − A multicenter, open label, Phase I/IIa study in relapsed or refractory NHL patients enriched with Mantle Cell Lymphoma – US & EU − High proportion of patients expressing CD32b in enriched population − High unmet medical need – despite th
Slide 15: Value proposition BI-1206 – key segments & value drivers
VALUE PROPOSITION BI-1206 – KEY SEGMENTS & VALUE DRIVERS Safety, chemo-free regimen and scientific rationale in Value drivers anti-CD20 refractory B-cell lymphoma are key drivers of • First-in-class in hematology - no direct competitors BI-1206 attractiveness. • BI-1206 shows a favorable safety prof
Slide 16: Targeting Tregs
TARGETING TREGS 1. Within a tumor 2. …killing of Tregs 3. …resulting in death microenvironment… induces activation of of tumor cells. CD8 T cells and TAMs… 16 16
Slide 17: Targeting TAMs
TARGETING TAMS 1. Within a tumor 2. …deletion or re- 3. …promotes CD8 T cell microenvironment… education of TAMs… and effector macrophage activation, resulting in death of tumor cells. 17 17
Slide 18: mAbs + oncolytic virus to target solid tumors
MABS + ONCOLYTIC VIRUS TO TARGET SOLID TUMORS 18
Slide 19: Milestones
MILESTONES H2 2018 - Start Phase I/IIa BI-1206/rituximab combination trial in NHL - Preclinical rationale Anti-CTLA-4/oncolytic virus, SITC Poster H1 2019 - BI-1206 /rituximab orphan drug designation (ODD) in mantle cell lymphoma - Podium Presentation SLAS 2019 Washington on F.I.R.S.T tm - Anti-FcγR
Slide 20: Proprietary manufacturing platform since 1988
PROPRIETARY MANUFACTURING PLATFORM SINCE 1988 • Supports fast and flexible production of proprietary programs • State of the art single use bioreactor (SUB) technology: 40L -1,000L batch sizes • Approved for Phase l to lll production • Track record of 30 years inspections • Consistent source of near
Slide 21: Financial Highlights
FINANCIAL HIGHLIGHTS Shareholder list includes reputable Jan.-June Jan.-June Jan.-Dec. institutions and sector specialist funds USD mln 2018 2017 2017 Largest shareholders 30 Sep. 2018 No. of shares Percentage of capital Net sales 2.5 2.7 5.3 and votes Research and development Van Herk Investments B
Slide 22: BioInvent Management Team
BIOINVENT MANAGEMENT TEAM Martin Welschof, Chief Executive Officer Björn Frendéus, Chief Scientific Officer Stefan Ericsson, Chief Financial Officer Andres McAllister, Chief Medical Officer Kristoffer Rudenholm Hansson, SVP Technical Operations 22 22
Slide 23: BioInvent's Scientific Advisory Board & Board of Directors
BIOINVENT’S SCIENTIFIC ADVISORY BOARD & BOARD OF DIRECTORS SAB BoD Martin Glennie, University of Southampton Leonard Kruimer, Chair (ex-Crucell, ProFibrix) Falk Nimmerjahn, Friedrich-Alexander University Vessela Alexieva, Employee representative Erlangen-Nürnberg Kristoffer Bissessar, (ex-Handelsban
Slide 24: Investment Highlights
INVESTMENT HIGHLIGHTS – Leading antibody immuno-oncology platform: • Advancing IO by overcoming tumor resistance • Validated by publications in top-tier journals and partnerships – Robust pipeline fueled by strong, fully integrated research engine: • 2 proprietary programs in the clinic - key readou
Slide 25: Thank You
Thank You
Slide 26: Appendix
Appendix
Slide 27: Value Proposition
Value Proposition Safety, chemo-free regimen and scientific rationale in anti-CD20 refractory B-cell lymphoma are key drivers of BI 1206 attractiveness FL MZL MCL Attractive opportunities: Attractive opportunities: Attractive opportunities: Key • 2nd Line (Relapsed/ refractory) • 2nd Line+ (Relapsed
Slide 28: MCL Market & Disease Overview
MCL MARKET & DISEASE OVERVIEW • Mantle cell lymphoma (MCL) is a rare, aggressive form of B-cell NHL, with tumor cells Treatment Paradigm originating in the mantle zone of the lymph node. Disease • Currently available treatment programs are not curative, and treatments for patients MCL Overview with
Slide 29: Market & Disease Overview: FL
Market & Disease Overview FL y, Follicular lymphoma (FL) is the most common indolent form of NHL. Typically, FL is staged based on the percentage of large cells occurring within the malignant B lymphocytes, with low grade FL generally characterized by slow Disease Overview progression. In contrast,
Slide 30: Market & Disease Overview: MZL
Market & Disease Overview MZL ease Overview Marginal zone lymphomas (MZLs) are a group of indolent B-cell NHLs that are segmented into 3 main sub-types: 1. Extranodal MZL or Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma (most prevalent; occurs outside the lymph nodes); 2. Nodal MZL (occurs in th
Slide 31: Overall anti-CD20 Hematology Market Overview
Overall anti-CD20 Hematology Market Overview (US $ (mIn)) WW anti-CD20 Sales by Indication (Available Branded & Generic; 2017-2024) 2017 2018 2019 2020 2021 2022 2023 @ Rituxan (Roche (NHL)) @ Gazyva (Roche (NHL)) ™ Gazyva (Roche (CLL)) Gazyva (NIPSH (NHL)) @ Truxima (Celltrion, Teva (NHL)) © Reditu
BioInvent International — Investor Presentation (October 2018) on 6ix